Dehydrogenative amide synthesis from alcohol and amine catalyzed by hydrotalcite-supported gold nanoparticles
作者:Jiangling Zhu、Yan Zhang、Feng Shi、Youquan Deng
DOI:10.1016/j.tetlet.2012.04.048
日期:2012.6
Hydrotalcite-supported nano-gold (Au/HT) was found to be a highly efficient heterogeneous catalyst for the dehydrogenative synthesis of amidefromalcohol and amine. Amines and alcohols with different structures could be converted into the amides under mild reaction conditions with up to 98% isolated yields. Mechanism exploration suggested that ester might be the reaction intermediate.
We report a mild and environmentally benign method for the synthesis of tertiary amines using alcohols as the alkylating reagents. Not only secondary amines such as piperazines but also amino acids and amino alcohols can be N-alkylated selectively. For N,O-benzyl protected amino alcohols, both N,O-de-benzylation and N-methylation were achieved in one-pot.
Microwave-assisted solvent-free parallel synthesis of thioamides
作者:Roger Olsson、Henrik C Hansen、Carl-Magnus Andersson
DOI:10.1016/s0040-4039(00)01360-5
日期:2000.10
Rapid parallelsynthesis of thioamides is described. A library of amides, synthesised by mixing acyl chlorides and diamines, was transformed into the corresponding thioamides utilising Lawesson's reagent as the oxygen/sulphur exchange reagent. Purification by solid-phase extraction afforded the library members in adequate purities and yields.
[EN] CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE MIMÉTIQUES DU CD4 EMPÊCHANT LA PÉNÉTRATION DU VIH-1 ET LEURS MÉTHODES D'UTILISATION
申请人:DANA FARBER CANCER INST INC
公开号:WO2013090696A1
公开(公告)日:2013-06-20
Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gpl20, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD- 556.